Sight Sciences Reports Q1 2025 Earnings and Outlook

Sight Sciences, Inc. ( (SGHT) ) has released its Q1 earnings. Here is a breakdown of the information Sight Sciences, Inc. presented to its investors.

Sight Sciences, Inc. is an eyecare technology company that develops and commercializes innovative interventional technologies aimed at transforming patient care in the eyecare industry, particularly focusing on glaucoma and dry eye diseases.

In its first quarter of 2025, Sight Sciences reported a total revenue of $17.5 million, marking a 9% decrease from the previous year. This decline was primarily attributed to reduced revenue from its Surgical Glaucoma segment, influenced by new Medicare coverage restrictions. Despite the revenue drop, the company maintained a gross margin of 86% and successfully launched its new OMNI Edge product.

Key financial metrics from the report include a reduction in operating expenses by 7% to $29.0 million and a net loss of $14.2 million, which is an improvement from the $16.3 million loss in the prior year. The company also reaffirmed its full-year revenue guidance of $70 to $75 million, reflecting anticipated challenges in the MIGS market due to Medicare policy changes.

Looking ahead, Sight Sciences remains focused on strategic initiatives such as expanding its MIGS market presence, securing reimbursement for its TearCare system, and advancing its product pipeline. The management is optimistic about the company’s growth potential and its ability to address significant unmet needs in the eyecare market.